Home
Random
Nearby
Log in
Settings
Donate
About Wikidata
Disclaimers
Search
(Q28072131)
Watch
English
Catch me if you can: Leukemia Escape after CD19-Directed T Cell Immunotherapies
scientific article
In more languages
edit
Statements
instance of
scholarly article
1 reference
stated in
PubMed
review article
1 reference
stated in
Europe PubMed Central
title
Catch me if you can: Leukemia Escape after CD19-Directed T Cell Immunotherapies
(English)
1 reference
stated in
PubMed
main subject
immunotherapy
1 reference
based on heuristic
inferred from title
leukemia
1 reference
based on heuristic
inferred from title
author
Marco Ruella
series ordinal
1
1 reference
stated in
Europe PubMed Central
PMC publication ID
5061074
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27761200%20AND%20SRC:MED&resulttype=core&format=json
retrieved
3 June 2020
author name string
Marcela V Maus
series ordinal
2
1 reference
stated in
Europe PubMed Central
PMC publication ID
5061074
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27761200%20AND%20SRC:MED&resulttype=core&format=json
retrieved
3 June 2020
language of work or name
English
1 reference
stated in
PubMed
publication date
28 September 2016
1 reference
stated in
PubMed
published in
Computational and Structural Biotechnology Journal
2 references
stated in
Crossref
stated in
Europe PubMed Central
PMC publication ID
5061074
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27761200%20AND%20SRC:MED&resulttype=core&format=json
retrieved
3 June 2020
volume
14
2 references
stated in
PubMed
stated in
Europe PubMed Central
PMC publication ID
5061074
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27761200%20AND%20SRC:MED&resulttype=core&format=json
retrieved
3 June 2020
page(s)
357-362
2 references
stated in
PubMed
stated in
Europe PubMed Central
PMC publication ID
5061074
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27761200%20AND%20SRC:MED&resulttype=core&format=json
retrieved
3 June 2020
cites work
Resistant mechanisms to BRAF inhibitors in melanoma
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5061074
retrieved
20 March 2017
Alternative molecular formats and therapeutic applications for bispecific antibodies
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5061074
retrieved
20 March 2017
Tumor regression in cancer patients by very low doses of a T cell-engaging antibody
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5061074
retrieved
20 March 2017
Chimeric antigen receptor T cells for sustained remissions in leukemia
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5061074
retrieved
7 April 2017
Efficacy and toxicity management of 19-28z CAR T cell therapy in B cell acute lymphoblastic leukemia
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5061074
retrieved
7 April 2017
Chimeric antigen receptor-modified T cells for acute lymphoid leukemia
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5061074
retrieved
7 April 2017
Dual CD19 and CD123 targeting prevents antigen-loss relapses after CD19-directed immunotherapies
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5061074
retrieved
29 September 2017
Chimeric Antigen Receptor T cells for B Cell Neoplasms: Choose the Right CAR for You.
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5061074
retrieved
29 September 2017
CD19 CAR immune pressure induces B-precursor acute lymphoblastic leukaemia lineage switch exposing inherent leukaemic plasticity
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5061074
retrieved
29 September 2017
Tandem CAR T cells targeting HER2 and IL13Rα2 mitigate tumor antigen escape
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5061074
retrieved
29 September 2017
Inotuzumab Ozogamicin versus Standard Therapy for Acute Lymphoblastic Leukemia
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5061074
retrieved
29 September 2017
The future of cancer treatment: immunomodulation, CARs and combination immunotherapy
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5061074
retrieved
29 September 2017
CD19 CAR-T cells of defined CD4+:CD8+ composition in adult B cell ALL patients
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5061074
retrieved
29 September 2017
T Cells Expressing CD19/CD20 Bispecific Chimeric Antigen Receptors Prevent Antigen Escape by Malignant B Cells
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5061074
retrieved
29 September 2017
Acquisition of a CD19-negative myeloid phenotype allows immune escape of MLL-rearranged B-ALL from CD19 CAR-T-cell therapy
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5061074
retrieved
29 September 2017
Convergence of Acquired Mutations and Alternative Splicing of CD19 Enables Resistance to CART-19 Immunotherapy
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5061074
retrieved
29 September 2017
Long-term survival and T-cell kinetics in relapsed/refractory ALL patients who achieved MRD response after blinatumomab treatment
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5061074
retrieved
29 September 2017
FDA Approval: Blinatumomab
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5061074
retrieved
29 September 2017
Causes of resistance and treatment choices of second- and third-line treatment in chronic myelogenous leukemia patients
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5061074
retrieved
29 September 2017
Phase I study of a bispecific ligand-directed toxin targeting CD22 and CD19 (DT2219) for refractory B-cell malignancies
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5061074
retrieved
29 September 2017
Safety and activity of blinatumomab for adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia: a multicentre, single-arm, phase 2 study
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5061074
retrieved
29 September 2017
T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5061074
retrieved
29 September 2017
Adoptive immunotherapy for cancer.
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5061074
retrieved
29 September 2017
Kinetics of tumor destruction by chimeric antigen receptor-modified T cells
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5061074
retrieved
29 September 2017
Combinational targeting offsets antigen escape and enhances effector functions of adoptively transferred T cells in glioblastoma.
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5061074
retrieved
29 September 2017
TanCAR: A Novel Bispecific Chimeric Antigen Receptor for Cancer Immunotherapy
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5061074
retrieved
29 September 2017
Anti-CD22-chimeric antigen receptors targeting B-cell precursor acute lymphoblastic leukemia
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5061074
retrieved
29 September 2017
Immunopharmacologic response of patients with B-lineage acute lymphoblastic leukemia to continuous infusion of T cell-engaging CD19/CD3-bispecific BiTE antibody blinatumomab
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5061074
retrieved
29 September 2017
A single-chain triplebody with specificity for CD19 and CD33 mediates effective lysis of mixed lineage leukemia cells by dual targeting.
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5061074
retrieved
29 September 2017
Mode of cytotoxic action of T cell-engaging BiTE antibody MT110.
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5061074
retrieved
29 September 2017
A history of cancer chemotherapy
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5061074
retrieved
29 September 2017
Treatment of SCID/human B cell precursor ALL with anti-CD19 and anti-CD22 immunotoxins
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5061074
retrieved
29 September 2017
A recombinant bispecific single-chain antibody, CD19 x CD3, induces rapid and high lymphoma-directed cytotoxicity by unstimulated T lymphocytes.
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5061074
retrieved
29 September 2017
Expression of immunoglobulin-T-cell receptor chimeric molecules as functional receptors with antibody-type specificity
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5061074
retrieved
29 September 2017
Expression of chimeric receptor composed of immunoglobulin-derived V regions and T-cell receptor-derived C regions.
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5061074
retrieved
2 June 2018
Lineage Switch in MLL-Rearranged Infant Leukemia Following CD19-Directed Therapy.
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5061074
retrieved
27 November 2018
Evolution to plasmablastic lymphoma evades CD19-directed chimeric antigen receptor T cells
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5061074
retrieved
27 November 2018
How to train your T cell: genetically engineered chimeric antigen receptor T cells versus bispecific T-cell engagers to target CD19 in B acute lymphoblastic leukemia.
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5061074
retrieved
27 November 2018
Phase II trial of the anti-CD19 bispecific T cell-engager blinatumomab shows hematologic and molecular remissions in patients with relapsed or refractory B-precursor acute lymphoblastic leukemia
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5061074
retrieved
27 November 2018
Long-term follow-up of hematologic relapse-free survival in a phase 2 study of blinatumomab in patients with MRD in B-lineage ALL
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5061074
retrieved
27 November 2018
Targeted therapy with the T-cell-engaging antibody blinatumomab of chemotherapy-refractory minimal residual disease in B-lineage acute lymphoblastic leukemia patients results in high response rate and prolonged leukemia-free survival.
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5061074
retrieved
27 November 2018
Chimeric receptors containing CD137 signal transduction domains mediate enhanced survival of T cells and increased antileukemic efficacy in vivo
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5061074
retrieved
27 November 2018
T-cell-mediated lysis of B cells induced by a CD19xCD3 bispecific single-chain antibody is perforin dependent and death receptor independent
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5061074
retrieved
27 November 2018
Development of a trispecific antibody conjugate that directs two distinct tumor-associated antigens to CD64 on myeloid effector cells
1 reference
stated in
PubMed
reference URL
https://pubmed.ncbi.nlm.nih.gov/27761200
retrieved
12 December 2020
based on heuristic
inferred from PubMed ID database lookup
A recombinant trispecific single-chain Fv derivative directed against CD123 and CD33 mediates effective elimination of acute myeloid leukaemia cells by dual targeting
1 reference
stated in
PubMed
reference URL
https://pubmed.ncbi.nlm.nih.gov/27761200
retrieved
12 December 2020
based on heuristic
inferred from PubMed ID database lookup
Complete Hematologic and Molecular Response in Adult Patients With Relapsed/Refractory Philadelphia Chromosome-Positive B-Precursor Acute Lymphoblastic Leukemia Following Treatment With Blinatumomab: Results From a Phase II, Single-Arm, Multicenter S
1 reference
stated in
PubMed
reference URL
https://pubmed.ncbi.nlm.nih.gov/27761200
retrieved
12 December 2020
based on heuristic
inferred from PubMed ID database lookup
Identifiers
DOI
10.1016/J.CSBJ.2016.09.003
2 references
stated in
Consolidated OpenCitations Corpus – April 2017
OpenCitations bibliographic resource ID
3289666
stated in
Europe PubMed Central
PMC publication ID
5061074
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27761200%20AND%20SRC:MED&resulttype=core&format=json
retrieved
3 June 2020
Fatcat ID
release_wvvggsgfuvbk3mnofjna33qrt4
1 reference
stated in
Fatcat
reference URL
https://api.fatcat.wiki/v0/release/wvvggsgfuvbk3mnofjna33qrt4
retrieved
24 November 2022
based on heuristic
mapped directly with Wikidata item
OpenCitations bibliographic resource ID
3289666
1 reference
stated in
Consolidated OpenCitations Corpus – April 2017
OpenCitations bibliographic resource ID
3289666
PMC publication ID
5061074
2 references
stated in
Consolidated OpenCitations Corpus – April 2017
OpenCitations bibliographic resource ID
3289666
stated in
Europe PubMed Central
PMC publication ID
5061074
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27761200%20AND%20SRC:MED&resulttype=core&format=json
retrieved
3 June 2020
PubMed publication ID
27761200
2 references
stated in
Consolidated OpenCitations Corpus – April 2017
OpenCitations bibliographic resource ID
3289666
stated in
Europe PubMed Central
PMC publication ID
5061074
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27761200%20AND%20SRC:MED&resulttype=core&format=json
retrieved
3 June 2020
Sitelinks
Wikipedia
(0 entries)
edit
Wikibooks
(0 entries)
edit
Wikinews
(0 entries)
edit
Wikiquote
(0 entries)
edit
Wikisource
(0 entries)
edit
Wikiversity
(0 entries)
edit
Wikivoyage
(0 entries)
edit
Wiktionary
(0 entries)
edit
Multilingual sites
(0 entries)
edit
